CELLMED (셀메드)

Cellmed Orthocellular Medicine and Pharmaceutical Association (셀메드 세포교정의약학회)
권호 표지
DOI QR코드

DOI QR Code

Receptor activator of nuclear factor-κB ligand in T cells and dendritic cells communication

  • Nam, Sun-Young (Department of Pharmacology, College of Korean Medicine, Kyung Hee University) ;
  • Jeong, Hyun-Ja (Inflammatory Disease Research Center and Biochip Research Center, Hoseo University)
  • Received : 2012.12.15
  • Accepted : 2013.02.20
  • Published : 2013.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

The receptor activator of NF-${\kappa}B$ ligand (RANKL), a member of the tumor necrosis factor ligand family, has extensive functions beyond osteoclast development. RANKL is expressed in many immune cells such as osteoblasts, osteocytes, marrow stromal cells, activated T cells, synovial cells, keratinocytes, and mammary gland epithelial cells as well as in various tissues. The ligation of RANK by RANKL promotes dendritic cells (DCs) survival through prosurvival signals and the up-regulation of the anti-apoptotic proteins Bcl-2 and Bcl-$x_L$ and plays a crucial role in DCs-mediated Th1 differentiation. Therefore, RANKL plays an important role in the regulation of DCs/T cells-mediated specific immunity. This review will briefly inform our current understanding of the role of RANKL signaling in T cells-DCs communication in the immune system.

Keywords

References

  1. Akiyama T, Shinzawa M, Akiyama N. RANKL-RANK interaction in immune regulatory systems. World J ORthop. 2012;3:142-150. https://doi.org/10.5312/wjo.v3.i9.142
  2. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko M E, Roux ER, Teepe MC, DuBose, RF, Cosman D, Galibert L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390:175-179. https://doi.org/10.1038/36593
  3. Boyce BF and Xing L. Biology of RANK, RANKL, and osteoprotegrin. Arthritis Res Ther. 2007;9:S1.
  4. Burger EH, van der Meer JW, Nijweide PJ. Osteoclast formation from mononuclear phagocytes: role of bone-forming cells. J Cell Biol. 1984;99:1901-1906. https://doi.org/10.1083/jcb.99.6.1901
  5. Caux C, Massacrier C, Vanbervliet B, Dubois B, Van Kooten C, Durand I, Banchereau J. Activation of human dendritic cells through CD40 cross-linking. J Exp Med. 1994;184:1263-1272.
  6. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science. 2000;288:2351-2354. https://doi.org/10.1126/science.288.5475.2351
  7. Ikedda T. Kasai M, Utsuyama M, Hirokawa K. Determination of three isoforms of the receptor activator of nuclear factor-kB ligand and their differential expression in bone and thymus. Endocrinology. 2001;142:1419-1426. https://doi.org/10.1210/en.142.4.1419
  8. Ito S, Wakabayashi K, Ubukata O, Hayashi S, Okada F, Hata T. Crytal structure of the extracellular domain of mouse RANK ligand at 2.2Å- resolution. J Biol Chem. 2002;277:6631-6636. https://doi.org/10.1074/jbc.M106525200
  9. Josien R, Wong BR, Li HL, Steinman RM, Choi Y. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol.1999;162:2562-2568.
  10. Kartsoginannis V, Zhou J, Jorwood NJ, Thomas RJ, Hards DK, Quinn JM, Niforas P, Ng KW, Martin TJ, Gillespie MT. Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeleta tissues. Bone. 1999;25:525-534. https://doi.org/10.1016/S8756-3282(99)00214-8
  11. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM. Activated T cell regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999;402:304-313. https://doi.org/10.1038/46303
  12. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165-176. https://doi.org/10.1016/S0092-8674(00)81569-X
  13. Lam J, Nelson CA, Ross FP, Teitelbaum SL, Fremont DH. Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J Clin Invest. 2001;108:971-979. https://doi.org/10.1172/JCI13890
  14. Leibbrandt A and Penninger JM. RANK/RANKL: Regulators of Immune responses and bone physiology. Ann N Y Acad Sci. 2008;1143:123-150. https://doi.org/10.1196/annals.1443.016
  15. Loser K, Mehling A, Loeser S, Apelt J, Kuhn A, Grabbe S, Schwarz T, Penninger JM, Beissert S. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med. 2006;12:1372-1379.
  16. Lum L, Wong BR, Josien R, Becherer JD, Erdjument-Bromage H, Schlondorff J, Tempst P, Choi Y, Blobel CP. Evidence for a role of a tumor necrosis factor-a(TNF-a)-converting Enzyme-like protease in shedding of TRANCE, a TNf family member Involved in osteoclastogenesis and dendritic cell survival. J Biol Chem. 1999;274:13613-13618. https://doi.org/10.1074/jbc.274.19.13613
  17. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, Sakai H. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun. 2000:275:768-775. https://doi.org/10.1006/bbrc.2000.3379
  18. Rodan GA, Martin TJ. Role of osteoblasts in hormonal control of bone resorption: a hypothesis. Calcif Tissue Int. 1981;33:349-351. https://doi.org/10.1007/BF02409454
  19. Schett G, Hayer S, Zerina J, Redlich K, Smolen JS. Mechanisms of disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol. 2005;1:47-54. https://doi.org/10.1038/ncprheum0036
  20. Tsuda E, Goto M, Mochizuki SI, Yano K, Kobayashi F, Morinaga T, Higashio K. Isolation of a novel cytokine from huma fibrobalsts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun. 1997;137-142.
  21. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006;12:17-25. https://doi.org/10.1016/j.molmed.2005.11.007
  22. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS, Frankel WN, Lee SY, Choi Y. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem.1997;272:25190-25194. https://doi.org/10.1074/jbc.272.40.25190
  23. Wong BR. Et al. TRANCE (tumor necrosis factor –related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med. 1997;186:2075-2080. https://doi.org/10.1084/jem.186.12.2075
  24. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS, Frankel WN, Lee SY, Choi Y. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal KInase in T cells. J Biol Chem. 1997;272:25190-25194. https://doi.org/10.1074/jbc.272.40.25190
  25. Wong BR, Josien R, Lee SY, Vologodskaia M, Steinman RM, Choi Y. The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor. J Biol Chem. 1998;273:28355-28359. https://doi.org/10.1074/jbc.273.43.28355
  26. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki SI, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998; 95:3597-3602. https://doi.org/10.1073/pnas.95.7.3597